Document is current
Any future updates will be listed below
-
Authors
Wang, Xuefeng https://orcid.org/0000-0001-5775-408X
Li, Tingyi
Eljilany, Islam https://orcid.org/0000-0001-6387-5419
Soupir, Alex https://orcid.org/0000-0003-1251-9179
Radmacher, Michael
Agius, Phaedra
Sukrithan, Vineeth
Ratan, Aakrosh https://orcid.org/0000-0002-0782-3056
McCarter, Martin https://orcid.org/0000-0001-8174-1713
Salhia, Bodour
Colman, Howard
Naqash, Abdul R.
Puzanov, Igor https://orcid.org/0000-0002-9803-3497
Arnold, Susanne https://orcid.org/0000-0001-6542-9551
Marin-Acevedo, Julian A.
Ganesan, Shridar
Churchman, Michelle https://orcid.org/0000-0002-6560-1056
Hwu, Patrick
Rodriguez, Paulo C. https://orcid.org/0000-0001-7480-6566
Dalton, William S.
Weiner, George J.
Tarhini, Ahmad A. https://orcid.org/0000-0002-3193-9702
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R01DE030493)
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 2 October 2025
First Online: 13 November 2025
Competing interests
: VS declares receiving research funding from Eli Lilly and Company and Crinetics Pharmaceuticals. Consulting for GE Health. Advisory Board member of Exelixis. Receiving speaking fees from Lantheus Pharmaceuticals. MM declares contracted research grants with Merck, Taiho, and the National Comprehensive Cancer Network. IP declares Program Leader (1.2 cal months) for NIH/NCI Cancer Center Support Grant (P30CA016056); consulting with Nouscom, Iovance, Nektar, and Regeneron; stock owner with Ideaya, Inc. HC declares advisory board/consultant: Best Doctors/Teladoc, Orbus Therapeutics, Bristol Myers Squibb, Regeneron, Novocure, and PPD/Chimerix; research funding (site PI/institutional contract): Orbus, GCAR, Array BioPharma, Karyopharm Therapeutics, Nuvation Bio, Bayer, Bristol Myers Squib, and Sumitomo Dainippon Pharma. To date, S.M.A. is a member of ASCO COI. A.A.T.declares contracted research grants with institutions from Bristol Myers Squib, Genentech-Roche, Regeneron, Sanofi-Genzyme, Nektar, Clinigen, Merck, Acrotech, Pfizer, Checkmate, OncoSec, Scholar Rock, InflaRx GmbH, Agenus; personal consultant/advisory board fees from Bristol Myers Squibb, Merck, Easai, Instil Bio, Clinigen, Regeneron, Sanofi-Genzyme, Novartis, Partner Therapeutics, Genentech/Roche, BioNTech, Concert AI, AstraZeneca outside the submitted work. The remaining authors declare no competing interests.
